With the U.S. approval Friday of Anesiva's lidocaine product Zingo, hospitalized children will have something less to fear: needle sticks from i.v. insertions and blood draws. (BioWorld Today)
The core management team that hit a home run with the first vascular endothelial growth factor (VEGF) inhibitor for the eye, which resulted in a $900 million merger and acquisition deal, is taking another swing at bringing new molecular entities to the marketplace with a newly formed company. (BioWorld Today)
The core management team that hit a home run with the first vascular endothelial growth factor (VEGF) inhibitor for the eye, which resulted in a $900 million merger and acquisition deal, is taking another swing at bringing new molecular entities to the marketplace with a newly formed company. (BioWorld Today)
